Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Kedrion 16% subcutaneous immunoglobulin in hypogammaglobulinaemia or agammaglobulinaemia
2010-020167-20Phase 2Terminated
- Sponsor
- Kedrion Biopharma
- Start
- Oct 2010
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of human normal immunoglobulin in hypogammaglobulinemia and agammaglobulinemia, sponsored by Kedrion Biopharma. Primary endpoint: Number of serious acute bacterial infections. Started Oct 2010; status: terminated.
02
Drugs
human normal immunoglobulin
03
Conditions
hypogammaglobulinemiaagammaglobulinemia
Beyond the preview
Go deeper on 2010-020167-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-020167-20.